Arcus Biosciences (RCUS) Capital Expenditures (2017 - 2025)

Arcus Biosciences' Capital Expenditures history runs 9 years deep, the most recent figure standing at -$1.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures fell 200.0% year-over-year to -$1.0 million; the TTM figure through Mar 2026 stood at -$1.0 million (down 116.67% YoY), while the FY2024 annual figure was $6.0 million, up 200.0% from the prior year.
• Capital Expenditures was -$1.0 million for Q4 2025 at Arcus Biosciences, down from $1.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.1 million in Q3 2021 to a low of -$16.6 million in Q4 2021.
• Historically, Capital Expenditures has averaged $882352.9 across 5 years, with a median of $2.0 million in 2022.
• Biggest YoY gain for Capital Expenditures was 8110.37% in 2021; the steepest drop was 701.52% in 2021.
• A 5-year view of Capital Expenditures shows it stood at -$16.6 million in 2021, then jumped by 112.07% to $2.0 million in 2022, then sank by 900.0% to -$16.0 million in 2023, then soared by 106.25% to $1.0 million in 2024, then tumbled by 200.0% to -$1.0 million in 2025.
• The last three Capital Expenditures figures came in at -$1.0 million (Q4 2025), $1.0 million (Q1 2025), and $1.0 million (Q4 2024), per Business Quant data.